Vascular endothelial growth factor family of ligands and receptors: Review

Otrock, Zaher K.; Makarem, J.; Shamseddine, Ali

doi:10.1016/j.bcmd.2006.12.003

Cited by 328 publications

(225 citation statements)

References 131 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…there is growing recognition of the central role that the VegF family plays in angiogenesis, the formation of new blood vessels, which is necessary for the growth and spread of a tumor (22). the VegF family consists of seven members, VEGF-A (also called VEGF), -b, -C, -D, -E, -F and placental growth factor (PIGF), which share eight cytokine residues in a VegF homology domain (23). VegF-A, particularly the VEGF165 and VEGF121 isoforms, plays an integral role in tumor angiogenesis both as an activator and survival factor in endothelial cells.…”

Section: Discussionmentioning

confidence: 99%

Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6

Aoyagi

Iinuma²,

Horiuchi³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

Abstract. For individualized bevacizumab-based therapy, non-invasive biomarkers are necessary. this study assessed the predictive value of plasma vascular endothelial growth factor (VegF)-A, soluble VegF receptor (sVegFr)-1 and sVegFr-2 levels as biomarkers for clinical response and survival in advanced colorectal cancer (crc) patients treated with bevacizumab and modified FOLFOX6 (mFOLFOX6). Forty-six unresectable advanced crc patients and 20 healthy controls were included in this study. crc patients were treated with bevacizumab and mFOLFOX6. Pretreatment plasma VegF-A, sVegFr-1 and sVegFr-2 levels were measured using the multiplex immunoassay. Plasma VEGF-A, sVEGFR-1 and sVEGFR-2 levels were significantly higher in crc patients than in the healthy subjects. the plasma sVegFr-1 levels in the responder patients [complete response (CR)/partial response (PR)] and stable disease (SD) patients were significantly lower than those in the progressive disease (PD) patients (CR/PR vs. PD, p=0.025; SD vs. PD, p=0.032), while the plasma VegF-A and sVegFr-2 levels did not show any significant differences between the two groups of patients. Patients with higher sVEGFR-1 levels showed a significantly poorer progression-free survival (PFS) and overall survival (os) than those with lower VegFr-1 levels. In contrast, VEGF-A and sVEGFR-2 did not show any significant relationship between PFS and OS according to the status of each level. In the multivariate cox proportional hazard regression analysis, sVEGFR-1 levels showed a significant relationship between PFS and OS. These results suggest that plasma sVegFr-1 levels have a predictive value for clinical response and survival in advanced crc patients treated with bevacizumab and mFOLFOX6. Larger scale studies are needed to further validate our results.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6

Aoyagi

Iinuma²,

Horiuchi³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…However, this argument is confounded by the expression of VEGFR-2 by a variety of non-vascular cell types (Ferrara et al, 2003;Otrock et al, 2007). It is possible that there may be speciesspecific differences in the process of retinal vascularization.…”

Section: 21mentioning

confidence: 99%

Vascular endothelial growth factor in eye disease

Penn

Madan

Caldwell

et al. 2008

Progress in Retinal and Eye Research

614

527

View full text Add to dashboard Cite

Collectively, angiogenic ocular conditions represent the leading cause of irreversible vision loss in developed countries. In the U.S., for example, retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration are the principal causes of blindness in the infant, working age and elderly populations, respectively. Evidence suggests that vascular endothelial growth factor (VEGF), a 40 kDa dimeric glycoprotein, promotes angiogenesis in each of these conditions, making it a highly significant therapeutic target. However, VEGF is pleiotropic, affecting a broad spectrum of endothelial, neuronal and glial behaviors, and confounding the validity of anti-VEGF strategies, particularly under chronic disease conditions. In fact, among other functions VEGF can influence cell proliferation, cell migration, proteolysis, cell survival and vessel permeability in a wide variety of biological contexts. This article will describe the roles played by VEGF in the pathogenesis of retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration. The potential disadvantages of inhibiting VEGF will be discussed, as will the rationales for targeting other VEGF-related modulators of angiogenesis.

show abstract

“…The VEGF family consists of seven members-VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, www.wjgnet.com VEGF-F, and placental growth factor (PlGF)-which share eight cysteine residues in a VEGF homology domain [9,10] . The members act through specific tyrosine kinase receptors, VEGFR-1, -2 and -3.…”

Section: Introductionmentioning

confidence: 99%

“…The members act through specific tyrosine kinase receptors, VEGFR-1, -2 and -3. VEGF-A acts through VEGFR-1 and -2 receptors, VEGF-C and -D act through VEGFR-2 and -3 [9,11] .…”

Section: Introductionmentioning

confidence: 99%

Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma

Al-Moundhri¹,

Al-Shukaili²,

Al-Nabhani³

et al. 2008

WJG

View full text Add to dashboard Cite

AIM:To analyze the serum levels and prognostic significance of vascular endothelial growth factor (VEGF) -A, -C, and -D, and their receptors, VEGFR-1 and -2 in gastric adenocarcinomas. METHODS:The serum levels of VEGF family members were measured in 76 control subjects and 76 patients with gastric adenocarcinoma using an enzyme-linked immunosorbent assay (ELISA). These measurements were correlated with clinco-pathological features and survival rates. RESULTS:The serum levels of VEGF-A and its receptor, VEGFR-1, were significantly higher in patients with gastric cancer than in healthy donors (t = 2.3, P = 0.02 and t = 4.2, P < 0.0001, respectively). In contrast, the serum levels of VEGF-D were significantly higher in control subjects than in patients (t = 2.9,

show abstract

Vascular endothelial growth factor family of ligands and receptors: Review

Cited by 328 publications

References 131 publications

Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6

Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6

Vascular endothelial growth factor in eye disease

Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma

Contact Info

Product

Resources

About